| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SK; DKK-1 |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DKK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DKK1抗体的3篇代表性文献，简要概括其研究内容：
1. **"Dickkopf-1 is a novel prognostic marker in glioblastoma patients"**
*作者：Mikheev et al. (2014)*
**摘要**：研究通过免疫组化发现DKK1在胶质母细胞瘤中高表达，使用抗DKK1抗体阻断其功能可抑制肿瘤细胞增殖，提示DKK1作为治疗靶点的潜力。
2. **"Therapeutic targeting of DKK1 suppresses tumor growth and bone metastasis in multiple myeloma"**
*作者：Yaccoby et al. (2009)*
**摘要**：利用人源化DKK1抗体在骨髓瘤小鼠模型中实验，结果显示抗体可恢复骨形成并减少溶骨性病变，同时抑制肿瘤生长。
3. **"DKK1-neutralizing antibodies prevent osteoporotic bone loss by modulating Wnt/β-catenin signaling"**
*作者：Li et al. (2016)*
**摘要**：开发DKK1中和抗体，通过激活Wnt通路促进成骨细胞分化，在骨质疏松动物模型中显著改善骨密度和微结构。
*注：以上文献可通过PubMed或Google Scholar输入标题查询全文。如需更多文献或具体领域研究，可进一步补充说明。*
DKK1 (Dickkopf-related protein 1) is a secreted glycoprotein that acts as a key antagonist of the Wnt/β-catenin signaling pathway, a critical regulator of embryonic development, tissue homeostasis, and cancer progression. By binding to the LRP5/6 co-receptors, DKK1 inhibits Wnt signaling, leading to reduced β-catenin stabilization and downstream gene expression. Dysregulation of DKK1 has been implicated in various diseases, including osteoporosis, rheumatoid arthritis, neurodegenerative disorders, and multiple cancers (e.g., multiple myeloma, breast, and lung cancers), where it often promotes tumor growth, angiogenesis, or immune evasion.
DKK1 antibodies are therapeutic or research tools designed to neutralize DKK1 activity, thereby restoring Wnt signaling. In oncology, anti-DKK1 antibodies may inhibit tumor proliferation, enhance bone formation in osteolytic lesions, and synergize with chemotherapy or immunotherapy. In bone diseases, they are explored to counteract DKK1-mediated suppression of osteoblast differentiation. Additionally, elevated DKK1 levels in cerebrospinal fluid or serum are studied as potential biomarkers for Alzheimer’s disease or certain cancers.
Developed as monoclonal antibodies (e.g., DKN-01 in clinical trials) or recombinant proteins, DKK1-targeting agents face challenges related to tissue specificity and signaling crosstalk. Nonetheless, they represent a promising strategy for modulating Wnt pathway activity in both mechanistic studies and therapeutic applications.
×
